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Abstract: HIV diversification facilitates immune escape and complicates antiretroviral therapy. In this
study, we take advantage of a humanized mouse model to probe the contribution of APOBEC3 muta-
genesis to viral evolution. Humanized mice were infected with isogenic HIV molecular clones (HIV-WT,
HIV-45G, HIV-ΔSLQ) that differ in their ability to counteract APOBEC3G (A3G). Infected mice re-
mained naïve or were treated with the RT inhibitor lamivudine (3TC). Viremia, emergence of drug re-
sistant variants and quasispecies diversification in the plasma compartment were determined throughout
infection. While both HIV-WT and HIV-45G achieved robust infection, over time HIV-45G replication
was significantly reduced compared to HIV-WT in the absence of 3TC treatment. In contrast, treatment
response differed significantly between HIV-45G and HIV-WT infected mice. Antiretroviral treatment
failed in 91% of HIV-45G infected mice while only 36% of HIV-WT infected mice displayed a similar
negative outcome. Emergence of 3TC resistant variants and nucleotide diversity were determined by
analyzing 155,462 single HIV reverse transcriptase (RT) and 6,985 vif sequences from 33 mice. Prior to
treatment, variants with genotypic 3TC resistance (RT-M184I/V) were detected at low levels in over a
third of all animals. Upon treatment, the composition of the plasma quasispecies rapidly changed leading
to a majority of circulating viral variants encoding RT-184I. Interestingly, increased viral diversity prior
to treatment initiation correlated with higher plasma viremia in HIV-45G but not in HIV-WT infected
animals. Taken together, HIV variants with suboptimal anti-A3G activity were attenuated in the absence
of selection but display a fitness advantage in the presence of antiretroviral treatment.IMPORTANCE
Both viral (e.g., reverse transcriptase, RT) and host factors (e.g., APOBEC3G (A3G)) can contribute
to HIV sequence diversity. This study shows that suboptimal anti-A3G activity shapes viral fitness and
drives viral evolution in the plasma compartment of humanized mice.
DOI: https://doi.org/10.1128/JVI.01543-19





Hernandez, Matthew M; Fahrny, Audrey; Jayaprakash, Anitha; Gers-Huber, Gustavo; Dillon-White,
Marsha; Audigé, Annette; Mulder, Lubbertus C F; Sachidanandam, Ravi; Speck, Roberto F; Simon, Vi-
viana (2019). Impact of suboptimal APOBEC3G neutralization on the emergence of HIV drug resistance





Impact of suboptimal APOBEC3G neutralization on the 1 
emergence of HIV drug resistance in humanized mice 2 
 3 
Matthew M. Hernandez1,2*, Audrey Fahrny3*, Anitha Jayaprakash4#, Gustavo Gers-4 
Huber3, Marsha Dillon-White
2, Annette Audigé3, Lubbertus C.F. Mulder2,5, Ravi 5 
Sachidanandam4,¶, Roberto F. Speck3,¶, Viviana Simon2,5,6,¶,$ 6 
 7 
1 The Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, 8 
New York, NY, USA 9 
2 Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, 10 
USA 11 
3 Division of Infectious Diseases and Hospital Epidemiology, University Hospital of Zurich, 12 
University of Zurich, Zurich, Switzerland 13 
4 Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New 14 
York, NY, USA 15 
5 Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount 16 
Sinai, New York, NY, USA 17 
6 Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at 18 
Mount Sinai, New York, NY, USA 19 
 20 
* M.M.H. and A.F. contributed equally to this work. The order of the first authors was 21 
determined on the basis of seniority.  22 
 23 
¶ R.S. (ravi.sachidanandam@mssm.edu), R.F.S. (roberto.speck@usz.ch) and V.S. are 24 
co-senior authors of this study. 25 
 26 
Current affiliations/address: 27 
# Girihlet, Inc. 355 30th Street, Oakland, CA-94609; www.girihlet.com 28 
  29 
JVI Accepted Manuscript Posted Online 4 December 2019
J. Virol. doi:10.1128/JVI.01543-19



































































Corresponding author ($): 30 
Dr. Viviana Simon 31 
Department of Microbiology 32 
Icahn School of Medicine at Mount Sinai 33 
Email: viviana.simon@mssm.edu 34 
 35 
 36 



































































ABSTRACT  38 
HIV diversification facilitates immune escape and complicates antiretroviral 39 
therapy. In this study, we take advantage of a humanized mouse model to probe the 40 
contribution of APOBEC3 mutagenesis to viral evolution. Humanized mice were infected 41 
with isogenic HIV molecular clones (HIV-WT, HIV-45G, HIV-SLQ) that differ in their 42 
ability to counteract APOBEC3G (A3G). Infected mice remained naïve or were treated 43 
with the RT inhibitor lamivudine (3TC). Viremia, emergence of drug resistant variants and 44 
quasispecies diversification in the plasma compartment were determined throughout 45 
infection. While both HIV-WT and HIV-45G achieved robust infection, over time HIV-45G 46 
replication was significantly reduced compared to HIV-WT in the absence of 3TC 47 
treatment. In contrast, treatment response differed significantly between HIV-45G and 48 
HIV-WT infected mice. Antiretroviral treatment failed in 91% of HIV-45G infected mice 49 
while only 36% of HIV-WT infected mice displayed a similar negative outcome. 50 
Emergence of 3TC resistant variants and nucleotide diversity were determined by 51 
analyzing 155,462 single HIV reverse transcriptase (RT) and 6,985 vif sequences from 33 52 
mice. Prior to treatment, variants with genotypic 3TC resistance (RT-M184I/V) were 53 
detected at low levels in over a third of all animals. Upon treatment, the composition of the 54 
plasma quasispecies rapidly changed leading to a majority of circulating viral variants 55 
encoding RT-184I. Interestingly, increased viral diversity prior to treatment initiation 56 
correlated with higher plasma viremia in HIV-45G but not in HIV-WT infected animals. 57 
Taken together, HIV variants with suboptimal anti-A3G activity were attenuated in the 58 
absence of selection but display a fitness advantage in the presence of antiretroviral 59 
treatment.  60 
 61 
IMPORTANCE  62 
Both viral (e.g., reverse transcriptase, RT) and host factors (e.g., APOBEC3G 63 
(A3G)) can contribute to HIV sequence diversity. This study shows that suboptimal anti-64 
A3G activity shapes viral fitness and drives viral evolution in the plasma compartment of 65 
humanized mice.  66 




































































HIV diversity is extensive on both an individual level and a global level. It drives 69 
viral adaptation in distinct cellular environments and facilitates escape from immune 70 
surveillance and antiretroviral therapy (ART,(1)). A combination of HIV features including 71 
high in vivo mutation rate, high replication rate and recombination between co-packaged 72 
genomes contributes to viral diversification (2, 3). Although the high mutation rate is 73 
caused by the error-prone nature of the HIV reverse transcriptase (RT, (4, 5)), the 74 
mutagenesis by host apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3 75 
(APOBEC3) cytidine deaminases also contributes to diversity (6-8). If left unchecked by 76 
HIV Vif, several of the APOBEC3 family members limit HIV replication, by mutating the 77 
viral cDNA during reverse transcription introducing guanosine to adenosine (G-to-A) (9-78 
13). Counteraction of APOBEC3G (A3G), APOBEC3F (A3F) and the stable haplotypes of 79 
APOBEC3H (A3H) by HIV Vif is essential for establishing a robust infection in vivo 80 
(reviewed in (10, 14)). However, proviruses in HIV infected patients frequently display high 81 
numbers of G-to-A mutations in dinucleotide contexts suggesting previous suboptimal 82 
anti-APOBEC3 activity (15-17). In fact, HIV Vif alleles obtained from the plasma and/or 83 
peripheral blood cell compartment of patients differ – to some extent – in their ability to 84 
counteract the different APOBEC3 proteins (18-20).  85 
Our understanding of the impact of HIV Vif variation on HIV/AIDS disease 86 
outcomes remains incomplete since such studies in patients are inherently limited in 87 
scope and descriptive in nature (11, 21, 22). With the advent of the humanized mouse 88 
model in the past decade, in vivo studies investigating HIV pathogenesis (23-25), novel 89 
therapeutic interventions (26-29) and viral evolution (30-32) under controlled experimental 90 
conditions have become possible. Experiments in different humanized mice systems (e.g., 91 
NOG, NSG, BLT) established that HIV Vif is necessary for infection (33, 34). Moreover, 92 
the impact of A3F, A3G and A3H on replication has been tested using HIV Vif mutant 93 
viruses that are defective in counteracting A3D, A3F, A3G or A3H (35-37). These studies 94 
show that the failure to neutralize A3G results in severe attenuation of viral replication with 95 
viruses unable to counteract A3G being less diverse than their wild-type counterparts (35, 96 
36). Thus, interrogation of A3G-driven HIV diversification in an “all or nothing” fashion 97 
indicates that a complete loss of anti-A3G activity results in HIV restriction and limits viral 98 



































































However, most circulating HIV strains maintain some activity against A3G such 100 
that experiments with viruses with suboptimal anti-A3G activity may provide a more 101 
relevant picture regarding the effects of partial APOBEC3 neutralization. Moreover, we 102 
reasoned that to directly test to what extent variation in APOBEC3 neutralization capacity 103 
influences HIV evolution in vivo, one needs to perturbate not only the HIV Vif-A3G axis 104 
(e.g., by using HIV Vif mutants) but also the viral equilibrium reached upon establishment 105 
of infection (e.g., by administrating an antiretroviral to apply selection pressure). Thus, in 106 
this study, we infected humanized mice with wild type and selected Vif mutant viruses and 107 
monitored infection in the plasma compartment over time in the presence and absence of 108 
antiretroviral treatment in the form of 3TC monotherapy. We assessed viral replication by 109 
longitudinally quantifying plasma viremia as well as viral diversification using a high-110 
resolution, molecular ID tag based deep sequencing approach. Our data indicate that 111 
suboptimal neutralization of A3G results in attenuated viral replication in the absence of 112 
selection but provides a replication advantage in the presence of 3TC antiretroviral 113 
treatment. 114 



































































MATERIALS AND METHODS 116 
Ethics statement 117 
Animal experiments were approved by the Cantonal Veterinary Office (#26/2011 & 118 
#93/2014) and performed in accordance to local guidelines and to the Swiss animal 119 
protection law. The Ethical Committee of the University of Zurich approved the 120 
procurement of human cord blood and written informed consent was provided prior to the 121 
collection of cord blood.  122 
Cell-lines 123 
HEK293T cells were obtained from ATCC (CRL-3216) and TZM-bl reporter cells were 124 
obtained from the AIDS Research and Reference Reagent Program, Division of AIDS, 125 
NIAID, National Institutes of Health (NIH AIDS Reagent Program, cat. 8129) (38-42). HEK 126 
293T cells and TZM-bl reporter cells were maintained in Dulbecco’s modified Eagle 127 
medium (DMEM, Fisher Scientific, cat. MT10-013-CV) supplemented with 10% fetal 128 
bovine serum (FBS) (Gemini Bio-Products) and 100 U/mL penicillin-streptomycin (Fisher 129 
Scientific, cat. MT30002CI). HEK 293T and TZM-bl cells were grown on 100mm FalconTM 130 
Standard Tissue Culture Dishes (Fisher Scientific, cat. 08-772E).  131 
Generation of viral stocks  132 
Isogenic molecular clones were derived from pNL4-3 (HIV-WT; NIH AIDS Reagent 133 
Program, cat. 114) (43), Replication competent molecular clones encoding Vif mutants 134 
E45G (HIV-45G) and SLQ144AAA (HIV-ΔSLQ) were generated as previously described 135 
(44). Viral stocks were generated by transfecting HEK293T cells using 4μg/mL 136 
polyethylenimine (PEI, Polysciences Inc., cat. 23966). Culture supernatants were 137 
collected 48 hours post-transfection, filtered and frozen at -80°C until further use. Viral 138 
stock concentrations were quantitated using an in-house p24 ELISA (45) and/or tittered on 139 
TZM-bl reporter cells as previously described (44). 140 
Generation of humanized mice 141 
Animals were housed under specific pathogen free conditions. Humanized mice were 142 
generated as previously described (29). Briefly, newborn immunodeficient NOD-scid IL-143 
2Rγ-null (NSG) mice (Jackson laboratory, Bar Harbor, ME) were irradiated 1-3 days after 144 



































































blood-derived CD34+ cells. Between 2 and 6 mice were transplanted with cells from the 146 
same donor. A total of 12 donors were used for the three infection experiments. 147 
Twelve to sixteen weeks after transplantation, human engraftment and de novo human 148 
immune system reconstitution in the mice were assessed by staining peripheral blood with 149 
monoclonal antibodies against the panhuman marker CD45 (Beckman Coulter, cat. 150 
B36294), CD19 (Biolegend, cat. 302212), CD3 (Biolegend, cat. 300308), CD4 (Biolegend, 151 
cat. 300518) and CD8 (Biolegend, cat. 301035). Flow-cytometry analyses were performed 152 
on a CyAN™ ADP Analyzer (Beckman Coulter, Brea, CA).  153 
A3H genotyping 154 
We determined the A3H genotype as described previously (46) for the twelve cord-blood 155 
donors whose CD34+ cells were used for the reconstitution of the mice. Briefly, genomic 156 
DNA was extracted from the CD34 negative flow-through fraction of the cord blood using 157 
DNeasy DNA isolation kit (QIAGEN, cat. 69504). The regions surrounding the A3H codon 158 
15 and the A3H codon 105 were amplified using Taq polymerase (QIAGEN, cat. 201203). 159 
The column-purified PCR products were sequenced and manually aligned using DNAstar 160 
(SeqMan, DNASTAR, Madison, WI).  161 
Infection and antiretroviral treatment of humanized mice 162 
Mice were infected intraperitoneally with 2×105 TCID50 per mouse of each of the 3 HIV 163 
clones in 200μL volume. Plasma viremia was measured using Cobas® Amplicor 164 
technology (Roche, Switzerland) at the described time points throughout the infection. The 165 
detection limit of the assay is 400 HIV RNA copies/mL.  166 
Lamivudine (3TC Epivir, GlaxoSmithKlein, UK) treatment was started 30 days post 167 
infection in the treatment group of the infected mice. 3TC tablets were weighed, 168 
pulverized and combined with food pellets as previously described (29).  169 
Amplification of HIV from plasma viral RNA 170 
Viral RNA was extracted from 140μL frozen plasma using the QIAamp Viral RNA Minikit 171 
(QIAGEN, cat. 52904) as per manufacturer’s instruction. 172 
For deep sequencing, cDNAs were synthesized using custom reverse transcription 173 
primers.(Supplemental Table 1; Integrated DNA Technologies). From 5’ to 3’, our first 174 



































































(accession: AF324493.2: 3336-3351), 8 bp randomized sequence (unique molecular ID 176 
(UMID)) and an additional 23 bp HIV-specific sequence (AF324493.2: 3305-3327). Viral 177 
cDNA was synthesized using the InvitrogenTM ThermoScript RT-PCR System (Thermo 178 
Fisher Scientific, cat. 11146016). Briefly, RNA and primer were denatured at 65C for 5 179 
min. ThermoScript reaction mix was added to the RNA and primer and incubated at 50C 180 
for 60 min, followed by an inactivation step of 85C for 5 min. 181 
Viral cDNA was column purified (Zymo Clean and Concentrator kit, cat. D4034) and 182 
amplified in a first round PCR using primers 1922 (AF324493.2: 2929-2946) and 1923 183 
(AF324493.2: 3337-3356). For the first round PCR used Pfx50 polymerase (94C for 2 184 
min, followed by 23 cycles of 93C for 15 sec, 48C for 30 sec, 68C for 60 sec and a final 185 
extension of 68C for 10 min) (Thermo Fisher Scientific, cat. 12355012). First round 186 
products were purified (Zymo Clean and Concentrator) and a second PCR was performed 187 
to add Illumina-based adapters using custom primers 1690 and one of 73 primers with 188 
distinct MiSeq barcode identifiers (Supplemental Table 1). The second round PCR used 189 
PfuUltra II Fusion HS Polymerase (95C for 2 min, followed by 25 cycles of 93C for 20 190 
sec, 50C for 20 sec, 72C for 15 sec and a final extension of 72C for 10 min) (Agilent 191 
Technologies, cat. 600672). Second round PCR products were confirmed by 192 
electrophoresis and purified by SPRIselect magnetic bead selection (Beckman Coulter, 193 
cat. B23317). 194 
To amplify vif sequences from plasma vRNA, a vif specific cDNA synthesis primer was 195 
used (4373). From 5’ to 3’, primer 4373 included a 16 bp T7 sequence, an 8 bp 196 
randomized sequence and 23 bp HIV-specific sequence (AF324493.2: 5386-5406). Viral 197 
cDNA was synthesized using the ThermoScript RT-PCR System and purified as 198 
described above. cDNAs were amplified in the first round PCR using primers 2402 199 
(AF324493.2: 4993-5012) and 2401 (T7). First round products were purified and amplified 200 
in a second round PCR using primers 2403 and one of 80 primers with distinct MiSeq 201 
barcode identifiers and complementarity to the T7 sequence. PCR cycling conditions were 202 
the same as used for the RT products.  203 
MiSeq Library Preparation and MiSeq Instrumentation 204 
Sequencing libraries were run on the Illumina MiSeq and sequenced as paired-end reads. 205 



































































amplicons and 393 bp vif amplicons) were quantitated by Qubit dsDNA HS Assay Kit 207 
(Thermo Fisher Scientific, cat. Q32854). To sequence 250 bp of the RT region, a 6pM 208 
final library was run with a 20% spike-in of PhiX Control V3 (Illumina, cat. FC-110-3001) 209 
for 2x150 cycles using MiSeq Reagent Kit v2 (300 cycles, Illumina, cat. MS-102-2002) or 210 
MiSeq Reagent Kit v3 (600 cycles, Illumina, cat. MS-102-3003). Custom sequencing 211 
primers were used for the forward (1692), index (3890), and reverse (3889) reads. To 212 
sequence a 269 basepair long region of vif, a 6pM final library was run with a 15% spike-213 
in of PhiX Control V3 for 2x150 cycles. Custom sequencing primers were used for the 214 
forward (4580), index (4577) and reverse (4578) reads  (Supplemental Table 1). 215 
Bioinformatic Pipeline for Sequence Analyses 216 
Custom Unix and Perl scripts were written to process FASTQ files. First, paired-end reads 217 
were merged using Paired-End reAd mergeR (47). Reads were aligned to pNL4-3 RT or 218 
vif reference sequences (AF324493.2) and filtered. Sequences were grouped by distinct 219 
UMIDs. A minimum of three high quality merged pair-end reads contained the same UMID 220 
were required to generate a consensus sequence. Consensus sequences were defined 221 
as sequences where each nucleotide reflected 70% or more of all nucleotides sequenced 222 
for that given position. Consensus sequences for sequences defined by a distinct UMID 223 
were identified using in-house scripts. Twenty-five UMIDs that differed by only one 224 
mismatch from the HIV template sequence were considered to be experimental artifacts 225 
and excluded from the analyses.  226 
Additional custom scripts were written to identify 3TC resistance mutations at RT codon 227 
184 and to compute overall mutation rates, GG-to-GA as well as GA-to-AA mutagenesis 228 
and the frequency of stop codons within the sequenced RT and vif regions. DNASP v5 229 
polymorphism software was used to calculate the nucleotide diversity (π), defined as the 230 
average pair-wise number of nucleotide differences per site in all possible pairs of 231 
consensus sequences per sample (48).  232 
Statistics 233 
Normality was assessed using the D’Agostino and Pearson test for numerical data such 234 
as baseline plasma viremia, changes in viremia, proportions of 3TC susceptible/resistant 235 
viral sequences, nucleotide diversity, and mutation rates. If groups passed normality tests, 236 



































































used. Otherwise, non-parametric Mann-Whitney or Wilcoxon matched pairs signed-rank 238 
tests were used. For categorical data (e.g., treatment failure/success), Fisher’s exact test 239 
was used. Linear regression models were used for replication kinetics and F-tests were 240 
used to compare slopes of curves of best fit. Finally, nonlinear regression methods 241 
(exponential (Malthusian)) using weighted least squares were used with extra sum-of-242 
squares F-test to compare nonlinear curves of best fit.  243 
Significance testing is reported as exact p-values in the text or using asterisks (*, p ≤ 0.05; 244 
**, p ≤ 0.01; ***, p ≤ 0.001; ****, p ≤ 0.0001). All statistics were performed using the built-in 245 
analysis packages from GraphPad Prism v8.0 Suite (GraphPad Software, Inc, La Jolla, 246 
CA).  247 
Data availability 248 
All raw FASTQ sequencing files have been made publicly available at the NCBI Short 249 
Read Archive (bioproject PRJNA579142, sample accessions SAMN13103784-250 
SAMN13103916). In addition, all in-house scripts for sequence read processing and data 251 
analyses can be accessed at https://github.com/SimonLab1850/Vif-pipeline. 252 




































































HIV-WT and HIV-45G establish productive infection in the humanized mouse model 255 
system. 256 
We performed three independent long-term infection experiments in 48 humanized 257 
NSG (hu-NSG) mice mimicking natural infection (Exp. 1; 85 days follow-up post infection) 258 
or treatment interventions (Exp. 2 and Exp. 3; 58-75 days of follow up post infection). Fig. 259 
1A depicts the time line for each experiment including the viruses used for infection and 260 
the time points at which blood samples were collected for further analysis (e.g., plasma 261 
viremia, HIV RNA sequence analysis). 262 
The three viruses selected for these experiments (HIV-WT, HIV-45G and HIV-263 
ΔSLQ) consist of isogenic clones of the HIV NL4-3 isolate that differ in their ability to 264 
counteract A3G. These mutants have been well characterized previously by us and others 265 
(12, 18, 44). Briefly, NL4-3 serves as HIV-WT. NL4-3 Vif counteracts A3G, A3F and A3D 266 
but is inactive against the stable A3H haplotypes (46). HIV-ΔSLQ fails to bind Cullin5 E3 267 
ligase complex due to three alanines in place of the SLQ BC-box motif (144-146) and, 268 
therefore, fails to counteract any of the APOBEC3 proteins. HIV-45G carries a single point 269 
mutation in codon 45 of Vif (HIV-45G) (18, 44, 49). This mutation in Vif results in 270 
attenuation but not complete abrogation of its activity against A3G while preserving 271 
activity against A3F and A3D (18). Importantly, residue 45 of Vif has not been associated 272 
with other Vif functions and is not involved in any other viral gene products (50, 51). HIV-273 
WT and HIV-45G replicate to comparable levels in primary human peripheral 274 
mononuclear cells while HIV-ΔSLQ fails to initiate a spreading infection in cell culture (44). 275 
Importantly, suboptimal neutralization of A3G by HIV-45G does not result in a sizeable 276 
replication defect in short-term cell culture infection experiments making it very well suited 277 
for in vivo infection experiments aimed at studying evolution in humanized mice.  278 
Hu-NSG mice were reconstituted with CD34+ cells isolated from umbilical cord 279 
blood and immune reconstitution was confirmed after 90 days prior to infection. A total of 280 
twelve different cord blood donors were used across the three independent infection 281 
experiments. Since HIV NL4-3 fails to counteract the active A3H haplotypes (46), we 282 
determined the A3H genotypes of all cord blood donors. None of the donors harbored two 283 
alleles of the active, stable A3H haplotypes. Five donors had one stable A3H haplotype 284 



































































 In all three experiments, we measured viremia at Day 30 post infection. Infection 286 
with HIV-WT and HIV-45G established comparable average viremia with no significant 287 
difference between the three independent infection experiments (Fig. 1B). In good 288 
agreement with previous findings, a functional HIV Vif was necessary to establish a 289 
productive infection since all four hu-NSG mice infected with HIV-SLQ displayed no 290 
detectable plasma viremia at Day 30 post infection (Fig. 1B). As anticipated, the presence 291 
of a single active A3H allele did not differentially influence the baseline viral load observed 292 
with the isogenic HIV-WT or HIV-45G viruses as tested by post-hoc multiple comparisons 293 
tests (Dunn’s) (p0.1084). 294 
 295 
Replication of HIV-45G but not HIV-WT is attenuated over time in humanized mice 296 
In the natural infection experiment (Exp. 1), we followed viral replication in the 297 
plasma compartment for nearly three months post infection. Plasma viremia was 298 
measured using molecular diagnostics at regular intervals. All productively infected 299 
animals (HIV-WT, N=14; HIV-45G, N=8) maintained viremia above the limit of detection 300 
until the end of the experiment. HIV-SLQ infected animals never displayed viral load 301 
measurements above 400 copies/ml (limit of detection of the assay). The change in 302 
plasma viremia over time is plotted in Fig. 2A. While HIV-WT infection resulted in an 303 
increase of replication over time in all but two animals, HIV-45G replication was 304 
attenuated in the majority of infected animals within 40-60 days post infection. The change 305 
in plasma viremia between baseline (i.e., Day 30 post infection) and endpoint was 306 
significantly different between the two viruses (HIV-45G: 0.77 log10 decrease versus HIV-307 
WT 0.43 log10 increase; p=0.0026). Taken together, in-vivo HIV-45G replication appears 308 
to be attenuated, although this trait becomes apparent only 50-60 days post infection. 309 
 310 
Suboptimal neutralization of A3G confers superior viral fitness in the presence of 311 
3TC in the humanized mouse model system. 312 
In the treatment intervention infection experiments (Exp. 2 and Exp. 3), animals 313 
robustly infected with either HIV-WT (N=11) or HIV-45G (N=11) were treated with 3TC 314 



































































58 in Exp. 3). Of note, the blood collection intervals in Exp. 3 were shorter than in 316 
Experiment 2 (4-7 day versus 14 day intervals). 317 
The initial virological response upon 3TC initiation was comparable between the 318 
two groups. Within the first two weeks of 3TC treatment both HIV-WT and HIV-45G 319 
viremia decreased to comparable nadirs (0.69 log10 versus 0.66 log10, respectively) (Fig. 320 
2C). One mouse (#120, infected with HIV-45G) was euthanized at Day 44 post infection 321 
as per animal safety protocol due to signs of wasting. Considering the overall change from 322 
baseline to experiment termination, HIV-WT replication decreased by 0.55 log10 in the 323 
presence of 3TC, whereas HIV-45G viremia had increased by 0.25 log10 from baseline 324 
(p=0.0045) (Fig. 2D). Moreover, HIV-45G infected animals experienced a larger (0.99 325 
log10 vs. 0.52 log10, p=0.0068, Fig. 2E) and faster (0.061 vs. 0.033 log10/day, p=0.0052, 326 
Fig. 2F) viral rebound from the initial lowest points reached upon 3TC treatment initiation.   327 
We also assessed 3TC treatment outcomes in a qualitative manner (e.g., 328 
treatment success versus failure, with success being defined as sustained reduction in 329 
viremia with less than 0.5 log10 rebound from the lowest points). Antiviral treatment was 330 
successful in 64% of HIV-WT infected mice but only 9% of HIV-45G infected mice (Fig. 331 
2G). Thus, HIV-45G infected mice had a significantly higher risk of failing treatment (RR: 332 
7.000; 95% CI 1.482 – 40.54; p=0.0237).  333 
Taken together, the replication of HIV-45G in the absence (Exp. 1) and in the 334 
presence of 3TC (Exp. 2 and Exp. 3) was very different (compare Figs. 2B and 2D). While 335 
the fitness of HIV-45G was attenuated over time in naïve animals, its replication was 336 
significantly less affected by 3TC than that of HIV WT suggesting the existence of a 337 
selection advantage.  338 
 339 
Dynamics of genotypic 3TC drug resistance  340 
The molecular mechanisms resulting in 3TC resistance are well described (52-58). 341 
Single point mutations in codon 184 of HIV RT emerge rapidly upon 3TC treatment both in 342 
vivo and in cell culture. RT-184I (ATG->ATA) and RT-184V (ATG->GTG) are the most 343 
common substitutions observed in HIV infected patients failing 3TC-containing ART (59) 344 
(Fig. 3A). These substitutions confer up to >1,000-fold reduced susceptibility to 3TC (53, 345 



































































leading to RT-184I is also within a dinucleotide context favored for A3G driven 347 
mutagenesis (e.g., GG-to-AG mutations, (ATGG->ATAG))(55, 60).  348 
To further investigate the in-vivo dynamics of resistance appearance, we used a 349 
next generation sequencing approach to analyze a 250 bp region of HIV RT (codon 177 to 350 
258) from cell-free HIV RNA (vRNA) present in the plasma compartment. We combined a 351 
unique molecular ID (UMID) strategy, to compensate for PCR-mediated amplification bias 352 
and errors (61, 62), with 150 bp paired-end Illumina sequencing chemistry. Briefly, two 353 
series of custom primers with an 8 bp randomized IDs were used to tag HIV vRNA during 354 
the reverse transcription step prior to amplification and sequencing. We sequenced a total 355 
of 111 vRNA samples obtained from 34 animals (primer #4372: 69 vRNA, 14 mice; primer 356 
#4633: 42 vRNA, 20 mice) generating a total of 9,705,468 high-quality paired-end reads 357 
representing 155,462 UMIDs (=individual HIV genomes). On average, we obtained 1,400 358 
UMIDs for each individual plasma sample generating between 1,333 and 17,854 unique 359 
RT consensus sequences for each infected animal over the course of the infection.  360 
This approach, importantly, provides sufficient resolution to identify minority viral 361 
populations and provide insights into the composition of the viral quasispecies. We first 362 
analyzed the mutations present at codon 184 of RT (Figs. 3B-3D). Minority 3TC resistant 363 
populations (defined as 1% or more of the overall number of UMIDs present in a given 364 
sample) were detectable after Day 30 post infection but prior to 3TC treatment in a third of 365 
the HIV-WT (N=4) and HIV-45G (N=5) infected mice (“pre-existing 3TC drug resistance” 366 
Fig. 3B). RT-184I resistant viruses were far more common than RT-184V (HIV-WT, 367 
p=0.0342; HIV-45G, p=0.0273) but generally made up less than 10% of the sampled 368 
circulating viruses in a given animal.  A combination of RT-184V and RT-184I was found 369 
in two animals (identified by the specific mouse number in Fig. 3B). Of note, when we 370 
stratified by treatment outcome, pre-existing 3TC drug resistance was not associated with 371 
treatment failure  (p=0.5227, Fisher’s exact test) and did not display any significant 372 
relationship with rate of nadir formation (HIV-WT, p=0.0762; HIV-45G, p=0.1115) or 373 
rebound rate (HIV-WT, p=0.3267; HIV-45G, p=0.0849).  374 
We next examined the dynamics of 3TC drug resistance in treated mice (Figs. 3C-375 
3D). In most animals, the 3TC-susceptible RT-184M majority was rapidly replaced with 376 
viruses encoding 3TC-resistant RT-184I or RT-184V alleles. On rare occasions, 377 



































































AAG (K)). The kinetics of RT-184I and RT-184V appearance in the plasma compartment 379 
were comparable in HIV-WT infected mice (p=0.2107, Fig. 3C) but RT-184I variants 380 
emerged 8.7 times more rapidly than RT-184V in HIV-45G infected mice (p=0.0035, Fig. 381 
3D). Overall, the relative proportion of the HIV-45G variants with RT-184V remained 382 
stable or declined over time while HIV-45G variants with RT-184I steadily increased (Fig. 383 
3D). Thus, emergence of viral variants with RT-184I is favored over that of RT-184V 384 
variants in animals infected with a virus displaying suboptimal A3G neutralization activity. 385 
Of note, M184I variants also appear often prior to M184V variants in 3TC treated patients 386 
(53, 58).  387 
 388 
Characterization of RT sequence diversity throughout the course of infection 389 
We next determined sequence diversity within the sequenced RT region beyond 390 
the 3TC drug resistance associated codon 184. We calculated the nucleotide diversity (π) 391 
among unique RT variants within a given plasma sample (63-65).  392 
Prior to 3TC treatment (Day 30 post infection), mice infected with HIV-WT and 393 
HIV-45G showed comparable nucleotide diversity in RT (p=0.6308, Fig. 4A). However, 394 
when we assessed the relationship between RT nucleotide diversity and the plasma viral 395 
load measured at Day 30 (prior to treatment initiation), we noted that nucleotide diversity 396 
positively correlated with the level of plasma viremia in HIV-45G infected animals (Fig. 397 
4C) while the opposite was true for HIV-WT infected animals (Fig. 4B). For this analysis 398 
we assumed an exponential (Malthusian) relationship based on the nature of HIV growth 399 
and diversity in acute infection (66, 67).  400 
We next explored how RT sequence diversity changed throughout the course of 401 
infection. While RT diversity remained largely unchanged in treatment-naïve animals, both 402 
HIV-WT and HIV-45G diversity in treated animals initially increased but then stabilized 403 
(Day 44 post infection, Fig. 4D-E). RT sequence diversity in 3TC treated mice was driven 404 
by drug resistance associated mutations.  Indeed, mutations at RT codon 184 contributed 405 
to 49-74% of HIV-WT and 45-69% of HIV-45G diversity (data not shown). When we 406 
excluded codon 184 from π analyses, any increases in diversity from baseline to Day 44 407 
through Day 75 were lost in the HIV-WT infected mice (p0.3097). However, when we did 408 



































































diversity starting at Day 58 through Day 75 post infection (p0.0430, Mann-Whitney). 410 
Thus, while the observed increase in RT sequence diversity is mainly due to selection of 411 
3TC resistant variants, other sites within RT contribute to viral diversity in HIV-45G 412 
infected mice. However, these non-drug resistance associated changes in HIV-45G 413 
viruses are only observed at later time points suggesting that they require more time to 414 
appear. 415 
Next, we explored the contribution of APOBEC3-driven mutagenesis to the RT 416 
sequence diversity. Towards this end, we measured G-to-A mutations within APOBEC3-417 
specific dinucleotide motifs (e.g., A3G: GG-to-AG; A3D/A3F: GA-to-AA, (68)). The 250 bp 418 
long region of RT that we sequenced contains 15 GG and 25 GA dinucleotides that could 419 
serve as APOBEC3 target motifs. At Day 30 post infection (prior to 3TC treatment), both 420 
HIV-WT and HIV-45G viruses carried more GG-to-AG than GA-to-AA mutations but the 421 
differences were only significant for the HIV-45G infected animals (p=0.0020, Fig. 5A). At 422 
Day 58 post infection in treated mice (Fig. 5C), GG-to-AG rates were higher than GA-to-423 
AA rates in both HIV-WT (p=0.0078) and HIV-45G (p=0.0020) infected mice. GG-to-AG 424 
mutation rates in HIV-WT and HIV-45G mice were comparable (p=0.6965) and were not 425 
due to selection of the RT-184I as rates were still comparable after analyses of sequences 426 
with codon 184 excluded (p=0.3445, Mann-Whitney).  427 
Due to its preferred dinucleotide context, A3G-induced mutagenesis can introduce 428 
mutations resulting in premature stop codons (e.g., UGG-to-UAG, (7, 69, 70)). Given that 429 
premature stop codons within RT are deleterious to replication (71-76), we were surprised 430 
to see that most infected animals (10/14 HIV-WT, 11/12 HIV-45G) had, at least, one 431 
plasma viral genome with mutations resulting in a stop codon upon protein translation. 432 
HIV-WT and HIV-45G viral populations in the plasma displayed stop codons 433 
predominantly at the four tryptophan (UGG-to-UAG or -UGA) codons (e.g., W212, W229, 434 
W239, W252) and rarely, at one of the six glutamine encoding codons (CAG-to-UAG, 435 
CAA-to-UAA; Q182, Q197, Q207, Q222, Q242, Q258). Of the 155,462 unique RT 436 
analyzed, 868 carried mutations leading to premature stop codon. The majority of the RT 437 
sequences (85%) only had a single stop codon but a small portion of sequences had two 438 
(11%), three (3%) or, at most, four (1%) stop codons. The rate of stop codons at Day 30 439 
and at Day 58 post infection was, however, comparable between the two groups 440 



































































Characterization of vif sequence diversity throughout the course of infection 442 
Lastly, we were interested in the extent to which the vif sequences changed over 443 
the course of infection. We used samples remaining from a subset of 14 animals included 444 
in Experiment #3 to sequence a 268 bp long region of HIV vif (corresponding with codons 445 
23 to 112) using a sequencing approach comprising UMID and Illumina 150 bp pair-end 446 
sequencing technology analogous to the approach taken for analyzing RT sequence 447 
diversity. In total, we generated 579,466 high quality paired-end reads representing 6,983 448 
distinct UMIDs from 27 plasma vRNA samples. 449 
We first looked for evidence of HIV-45G revertants at Day 30 and Day 58 post 450 
infection in five Vif-45G infected animals (Fig. 6A). Viruses in HIV-45G infected animals 451 
carrying the Vif-45E reversion were rare at Day 30 post infection (less than 1% in all five 452 
animals) but ranged between 0.5% and 9% of the plasma virus population present at Day 453 
58 post infection (Fig. 6A). These data suggest that the Vif-45G genotype is quite stable 454 
over time. 455 
Since it has been suggested that vif diversification may be distinct from that of 456 
other HIV genes depending on the selective pressures exerted (7, 70, 77), we analyzed 457 
the nucleotide diversity, APOBEC3 driven mutagenesis and the rate of stop codons for the 458 
vif region sequenced (Figs. 6B-6G). The 268 bp long region of vif that we sequenced 459 
contains 17 or 18 GG (HIV-WT, Vif E45 = GAA; HIV-45G, Vif E45G = GGA) and 22 GA 460 
dinucleotides that could serve as APOBEC3 target motifs. Prior to treatment (Day 30 post 461 
infection), vif sequence diversity (Fig. 6B), GG-to-AG/GA-to-AA mutation rates (Fig. 6C) 462 
and stop codon frequency (Fig. 6C) were comparable between HIV-WT and HIV-45G 463 
infected mice. However, at Day 58 post infection, the Vif diversity was significantly higher 464 
in HIV-45G viruses compared to their wild-type counterparts (p=0.0357, Fig. 6E). 465 
APOBEC3 mutagenesis (GG-to-AG, GA-to-AA or rate of stop codon, Figs. 6F-6G) were 466 
comparable between the two groups.  467 
Taken together, HIV-45G genotype can revert to wild-type Vif, but it only accounts 468 
for a small percentage of the circulating plasma variants in a portion of the mice tested. 469 
Moreover, there is some evidence suggesting that RT and vif regions diversity is caused 470 
by different mechanisms.  471 




































































Proviruses with footprints of past cytidine deamination are found in many, if not all, 474 
HIV infected patients (11, 17, 22, 60, 78-83). Nonetheless, it remains controversial to what 475 
extent APOBEC3-driven mutagenesis contributes to viral evolution and HIV/AIDS disease 476 
outcome in vivo. Some clinical studies find correlations between frequency of G-to-A 477 
mutations in proviruses and plasma viral loads (7, 82, 84), whereas others fail to find such 478 
associations (17, 83, 85). Controlled experiments in cell culture, however, provide strong 479 
experimental evidence in support of the notion that A3G-driven mutagenesis facilitates 480 
HIV diversification and promote escape from selection pressure (44, 69, 86). In the current 481 
study, we perform controlled, in vivo infection experiments to provide new insights into the 482 
dynamics of HIV diversification within the plasma compartment of humanized mice in the 483 
absence and presence of selection pressure. We show that suboptimal neutralization of 484 
A3G shapes the phenotype of circulating viruses and compromises 3TC treatment 485 
outcomes.  486 
Previous studies in cell culture (20, 44, 87) and in humanized mice (33-37) have 487 
examined the role of APOBEC3 proteins in HIV replication and pathogenesis in vivo but 488 
our study dissects the impact of A3G-driven mutagenesis in the context of viral evolution 489 
by introducing selection in the form of antiretroviral treatment. Moreover, we focus on viral 490 
diversification within the plasma compartment, which reflects the actively replicating viral 491 
quasispecies in an immediate and dynamic manner. HIV-45G, which has suboptimal anti-492 
A3G activity, is less fit than HIV-WT in treatment-naïve animals overtime (Fig. 2A) 493 
pointing to the slow accumulation of mutations. Conversely, HIV-45G responds less well 494 
to and rebounds more rapidly in the presence of 3TC treatment (Figs. 2B-2D). Thus, 495 
complete inactivation of A3G is dispensable for initiating a productive and robust infection 496 
of humanized mice and suboptimal A3G neutralization can be beneficial to HIV for 497 
overcoming evolutionary bottlenecks such as selection pressure by antiretroviral drugs. Of 498 
note, a limitation of our experimental system is that the hu-NSG mouse model system 499 
used in this study lacks robust immunologic pressures against HIV (i.e., CD4+/CD8+ T 500 
cell responses or antibodies (88)) and thus, does not recapitulate well the continued 501 
selection pressure exerted by the adaptive immune system.  502 
Sequencing technologies have dramatically improved over the last decade 503 



































































UMIDs with Illumina pair-end sequencing to analyze >150,000 individual RT sequences 505 
sampling approximately 1,170 distinct viral genomes for each individual time point. 506 
Previous studies in humanized mice examined sequence diversity using bulk amplification 507 
followed by sequencing of individual clones (33-36) or by single-genome sequencing 508 
(SGS, (36)). The first of these methods fails to reliably distinguish between individual 509 
variants and may skew viral diversity measurements due to PCR errors or bias (61, 62). 510 
SGS is regarded as gold standard in the field since it analyses distinct genomes and 511 
provides information on large regions. However, the approach is very work intensive and 512 
costly, limiting the numbers of genomes that can be sampled (89-91). For example, one 513 
previous study used SGS to analyze a total of 265 genomes from eight mice (36). In our 514 
study, in contrast, we analyzed on average 1,400 RT sequences per infected animal 515 
providing us with solid data on minority viral populations. It has to be noted that even at 516 
our high sequencing depth, we only sample a limited portion of the viruses circulating in 517 
the plasma compartment (i.e., average plasma viremia at Day 30 post infection is 89,620 518 
copies/mL). Despite this limitation, our sequencing data revealed a number of previously 519 
overlooked facts regarding the dynamics of HIV evolution in vivo. First, we found that 3TC 520 
drug resistant viral variants were found, in a third of the animals, prior to 3TC treatment 521 
initiation (Fig. 3B). Pre-existing 3TC resistance was, however, not linked to more rapid 522 
treatment failure suggesting that these viruses may not be fully replication competent 523 
and/or that drug resistant variants arise de novo upon initiation of antiretroviral treatment. 524 
Second, we noted a positive correlation between increased RT sequence diversity and 525 
high plasma viremia in HIV-45G infected animals after 30 days of unchecked replication 526 
(Fig. 4B). This association is surprising since conventional wisdom would predict the 527 
opposite to be true. Indeed, this is exactly what we observe for HIV-WT infections where 528 
increased RT diversity is associated with lower plasma viremia (Fig. 4C).  Third, the 529 
kinetics with which the two drug resistant variants RT-184I and RT-184V appeared in the 530 
plasma differed between the two viruses.  In mice infected with HIV-45G, the RT-184I 531 
variants arose at a rate 8.3-times faster than that of RT-184V variants, whereas 532 
emergence rates for these variants were comparable in mice infected with HIV-WT (Fig. 533 
3D). However, RT-184I did not appear more readily in HIV-45G infected animals. This 534 
could be due to the fact that our earliest collection time point was ten days after treatment 535 



































































expand in tissue compartments with the plasma compartment being a mere reflection after 537 
the fact.  538 
Taken together, future studies investigating the viral diversification at the viral 539 
RNA, cellular viral RNA and proviral level in vivo in the humanized model will provide 540 
further insights into how viral quasispecies shaped by APOBEC3 mutagenesis inform on 541 
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FIGURE LEGENDS 552 
 553 
Fig. 1: Infection of humanized mice with HIV-Vif variants.   554 
(A) Newborn NOD-scid IL-2Rγ-null (NSG) mice were irradiated after birth and 555 
transplanted with human donor cord blood-derived CD34+ cells. Mice were infected 556 
intraperitoneally with 2×105 TCID50 of virus (HIV-WT, HIV-45G or HIV-SLQ). The 557 
specifics for each of the three infection experiments are provided in the time-lines. Plasma 558 
was collected at the indicated time points for viremia measurements and sequence 559 
analysis.  560 
(B) Comparison of the plasma viremia Day 30 post infection (baseline) in mice infected 561 
with the different viruses in the three different experiments. The lower limit of detection of 562 
the assay is 400 copies/mL (cp/mL). The mean and standard deviations of the viral loads 563 
are depicted.  Viremia for HIV-SLQ is significantly different from HIV-WT or HIV-45G  (p 564 
≤ 0.0020, Mann-Whitney). 565 
 566 



































































Fig 2: Viral replication in humanized mice in the absence or presence of 3TC treatment.  568 
(A) Spaghetti plots depicting the change in viremia relative to baseline viral load (Day 30 569 
post infection) of individual untreated mice (pale lines) and mean change in viremia in 570 
untreated mice (bold lines). 571 
(B) Barplots depicting the change in viremia at the end of infection (last available 572 
timepoint) versus baseline viremia in untreated mice. Means and standard deviation are 573 
depicted. p = 0.0026 by unpaired student’s t-test.  574 
(C) Spaghetti plots depicting the change in viremia in 3TC treated mice.  575 
(D) Barplots depict the overall change in viremia at the end of infection in 3TC treated 576 
mice with means and standard deviations. p = 0.0045 by unpaired student’s t-test.  577 
(E) Rebound viremia – defined as the maximum fold rebound viral load from nadir 578 
(maximum level of suppression observed; log(VLmax/VLnadir) – is depicted for mice treated 579 
with 3TC. Each point represents an individual mouse. Mean and standard deviations are 580 
depicted. p = 0.0068 by Mann-Whitney test.  581 
(F) Rate of rebound was also measured over the time from nadir to maximum viremia. 582 
Means and standard deviations depicted. p = 0.0052 by unpaired student’s t-test.  583 
(G) Qualitative assessment of treatment outcomes. 3TC treatment was defined as 584 
successful if the viral rebound was less than 0.5 log10 from nadir. Conversely, treatment 585 
failure was met if the viral rebound was greater than 0.5 log10 from nadir. p = 0.0237, 586 
Fisher’s exact test.  587 
 588 



































































Fig. 3: Drug resistance development in 3TC treated mice.  590 
(A) Genotypic 3TC drug resistance is due to single point mutations in codon 184 of HIV 591 
reverse transcriptase (RT) gene. Methionine (M184) represents the susceptible wild-type 592 
sequence while RT-184I or RT-184V render the virus resistant to 3TC.  593 
(B) Pre-existing 3TC resistance detected at Day 30 post infection (”D30”) prior to 3TC 594 
treatment initiation. Each dot represents the percentage of viruses encoding RT-184I or 595 
RT-184V in a given mouse. Minority 3TC resistant viral populations were defined as 596 
representing at least 1% of the total number of UMIDs sequenced for each mouse at this 597 
time point (dotted line). Some mice harbored both M184I/V variants and are indicated by 598 
mouse ID number. (*) p ≤ 0.05, Wilcoxon matched pairs signed rank test.  599 
(C) Spaghetti plots longitudinally depicting the relative proportion of 3TC susceptible and 600 
resistant viral variants in HIV-WT infected mice. M184, RT-184I and RT-184V data for 601 
individual mice (pale lines) and mean proportions at each timepoint (bold lines) are 602 
depicted. Slopes of lines of best fit were calculated to measure kinetics of RT-184M, RT-603 
184I and RT-184V variants. Slopes compared by F-test (ns: not significant, p = 0.5372).  604 
(D) Spaghetti plots longitudinally depicting the relative proportion of 3TC susceptible and 605 
resistant viral variants in HIV-45G infected mice. Slopes compared by F-test (p = 0.0035).  606 
 607 



































































Fig. 4: Genetic diversity of circulating viruses in the plasma of infected mice.  609 
(A) Dot plot depicting nucleotide diversity (π) in the sequenced HIV RT gene in HIV-WT 610 
and HIV-45G infected mice prior to initiation of 3TC treatment (30 Days post infection). 611 
Points represent π in each mouse and bars depict means.  612 
(B) Diversity and viremia (VL) data in mice infected with HIV-WT prior to treatment were fit 613 
to a weighted nonlinear exponential growth (Malthusian) model. Best fit curve and 95% 614 
confidence interval (CI) bands are portrayed. The corresponding curve equation and 615 
weighted correlation coefficient (R) are depicted above.  616 
(C) Diversity and VL data in mice infected with HIV-45G prior to treatment fit to an 617 
exponential growth model as in (B). 618 
(D) Diversity in plasma viruses of HIV-WT infected mice over time (untreated left, 3TC 619 
treated right). Significance determined by Mann-Whitney test (*, p ≤ 0.05; **, p ≤ 0.01; ***, 620 
p ≤ 0.001; ****, p ≤ 0.0001). 621 
(E) Diversity in plasma viruses of HIV-45G infected mice over time (untreated left, 3TC 622 
treated right). Significance determined by Mann-Whitney test (*, p ≤ 0.05; **, p ≤ 0.01; ***, 623 
p ≤ 0.001; ****, p ≤ 0.0001). 624 
 625 



































































Fig. 5: Mutagenesis in HIV RT gene in plasma viruses of HIV infected mice.  627 
(A) Dot plots depicting fractions of GG and GA dinucleotides mutated to AG (GG-to-AG) 628 
and AA (GA-to-AA), respectively, in individual mice (points) prior to 3TC treatment (Day 629 
30 post infection). Bars depict means. p = 0.0020, Wilcoxon matched pairs signed rank 630 
test. 631 
(B) Stop codons were quantitated across all plasma sequences and a stop codon rate for 632 
every 1,000 codons sequenced was calculated for infected mice at Day 30 post infection. 633 
(C) Fraction of GG-to-AG or GA-to-AA dinucleotides mutations in plasma samples at Day 634 
58 post infection in 3TC treated mice. (*) p ≤ 0.05, (**) p ≤ 0.01, Wilcoxon matched pairs 635 
signed rank test. 636 
(D) Stop codon rate in plasma samples from Day 58 post infection.  637 
 638 



































































Fig. 6: Characterizing HIV Vif mutations in infected mice.  640 
(A) Genotype of Vif codon 45 in five mice infected with HIV-45G and treated with 3TC 641 
from 30 to 58 Days post infection. Percentage of 45G and revertant E45 sequences 642 
indicated on stacked barplots. Percentages of the latter are annotated, as well.  643 
(B) Dot plots depicting nucleotide diversity (π) in Vif sequences in individual mice (points) 644 
infected with HIV-WT or HIV-45G at 30 Days post infection (prior to 3TC treatment). Bars 645 
depict means. 646 
(C) Dot plots depicting fractions of GG and GA dinucleotides mutated to AG (GG-to-AG) 647 
and AA (GA-to-AA), respectively, in individual mice (points) at 30 Days post infection. 648 
Bars depict means.  649 
(D) Stop codon rates were quantitated across plasma Vif sequences at Day 30 post 650 
infection (as in Fig. 5B).  651 
(E) Dot plots depicting π in Vif sequences in individual mice (points) at Day 58 post 652 
infection in 3TC treated mice. p = 0.0357, Mann-Whitney test.  653 
(F) Fraction of GG-to-AG or GA-to-AA dinucleotides mutated in Vif at Day 58 post 654 
infection in 3TC treated mice.  655 
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